SK Aurora

3.9k total citations · 2 hit papers
22 papers, 2.9k citations indexed

About

SK Aurora is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, SK Aurora has authored 22 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 11 papers in Pathology and Forensic Medicine and 7 papers in Neurology. Recurrent topics in SK Aurora's work include Migraine and Headache Studies (20 papers), Trigeminal Neuralgia and Treatments (9 papers) and Botulinum Toxin and Related Neurological Disorders (6 papers). SK Aurora is often cited by papers focused on Migraine and Headache Studies (20 papers), Trigeminal Neuralgia and Treatments (9 papers) and Botulinum Toxin and Related Neurological Disorders (6 papers). SK Aurora collaborates with scholars based in United States, United Kingdom and Netherlands. SK Aurora's co-authors include HC Diener, DW Dodick, SD Silberstein, CC Turkel, RB Lipton, RE DeGryse, K.M.A. Welch, F. Wilkinson, Yue Cao and K.M.A. Welch and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and Headache The Journal of Head and Face Pain.

In The Last Decade

SK Aurora

22 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

2010 744 citations SK Aurora, DW Dodick et al. Cephalalgia profile →
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

2010 676 citations HC Diener, DW Dodick et al. Cephalalgia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
SK Aurora United States	14	2.5k	1.6k	1.1k	744	501	22	2.9k
Mark C. Kruit Netherlands	24	2.4k 0.9×	1.3k 0.8×	459 0.4×	552 0.7×	660 1.3×	62	3.2k
DW Dodick United States	25	3.0k 1.2×	2.1k 1.3×	1.6k 1.4×	1.0k 1.3×	198 0.4×	58	3.6k
Anish Bahra United Kingdom	16	2.5k 1.0×	2.0k 1.2×	1.4k 1.2×	238 0.3×	146 0.3×	38	2.7k
Nicola Giffin United Kingdom	14	1.5k 0.6×	831 0.5×	522 0.5×	224 0.3×	362 0.7×	30	1.8k
Shazia Afridi United Kingdom	16	1.2k 0.5×	841 0.5×	549 0.5×	322 0.4×	176 0.4×	32	1.8k
Letizia Maria Cupini Italy	31	1.1k 0.4×	511 0.3×	542 0.5×	472 0.6×	323 0.6×	58	2.6k
Joseph Hulihan United States	23	1.6k 0.6×	672 0.4×	493 0.4×	561 0.8×	103 0.2×	39	2.1k
Ottar Sjaastad Norway	36	3.2k 1.3×	2.8k 1.7×	1.5k 1.3×	557 0.7×	111 0.2×	161	4.1k
Sheena K. Aurora United States	25	1.7k 0.7×	946 0.6×	761 0.7×	292 0.4×	240 0.5×	48	1.9k
G Géraud France	18	1.1k 0.5×	667 0.4×	458 0.4×	235 0.3×	160 0.3×	66	1.5k

Countries citing papers authored by SK Aurora

Since Specialization

Citations

This map shows the geographic impact of SK Aurora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SK Aurora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SK Aurora more than expected).

Fields of papers citing papers by SK Aurora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SK Aurora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SK Aurora. The network helps show where SK Aurora may publish in the future.

Co-authorship network of co-authors of SK Aurora

This figure shows the co-authorship network connecting the top 25 collaborators of SK Aurora. A scholar is included among the top collaborators of SK Aurora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SK Aurora. SK Aurora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ford, James H., Antje Tockhorn‐Heidenreich, Virginia L. Stauffer, et al.. (2019). Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. European Journal of Neurology. 27(4). 609–618. 24 indexed citations

2.

Mulleners, Wim M., Miguel J. A. Láinez, Michel Lantéri‐Minet, et al.. (2019). A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study. Journal of the Neurological Sciences. 405. 128–128. 11 indexed citations

3.

Hansen, Jakob Møller, RB Lipton, DW Dodick, et al.. (2013). Migraine headache is present in the aura phase – a prospective study. The Journal of Headache and Pain. 14(S1). 10 indexed citations

4.

Aurora, SK, DW Dodick, RE DeGryse, & CC Turkel. (2013). OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT. The Journal of Headache and Pain. 1(Suppl 1). P199–P199. 1 indexed citations

5.

Aurora, SK, David W. Dodick, HC Diener, et al.. (2013). OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurologica Scandinavica. 129(1). 61–70. 126 indexed citations

6.

Aurora, SK, DW Dodick, RE DeGryse, & CC Turkel. (2013). OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT. The Journal of Headache and Pain. 14(S1). 1 indexed citations

7.

Hansen, Jakob Møller, RB Lipton, DW Dodick, et al.. (2013). Migraine headache is present in the aura phase – a prospective study. The Journal of Headache and Pain. 1(Suppl 1). P130–P130. 4 indexed citations

8.

Diener, HC, DW Dodick, SK Aurora, et al.. (2011). placebo-controlled phase of the PREEMPT 2 trial OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized,. 64 indexed citations

9.

Lipton, Richard B., Brian M. Grosberg, Peter J. McAllister, et al.. (2011). OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 77(15). 1465–1472. 113 indexed citations

10.

Diener, HC, DW Dodick, SK Aurora, et al.. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 30(7). 804–814. 676 indexed citations breakdown →

11.

Aurora, SK, DW Dodick, CC Turkel, et al.. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 30(7). 793–803. 744 indexed citations breakdown →

12.

Aurora, SK. (2009). Is Chronic Migraine One End of a Spectrum of Migraine or a Separate Entity?. Cephalalgia. 29(6). 597–605. 24 indexed citations

13.

Aurora, SK & F. Wilkinson. (2007). The Brain is Hyperexcitable in Migraine. Cephalalgia. 27(12). 1442–1453. 219 indexed citations

14.

Aurora, SK, et al.. (2003). The Threshold for Phosphenes is Lower in Migraine. Cephalalgia. 23(4). 258–263. 94 indexed citations

15.

Aurora, SK, et al.. (2002). Functional imaging of subcortical nociceptive structures in response to treatment of chronic daily headache. 3. 919. 4 indexed citations

16.

Cao, Yue, et al.. (2002). Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology. 59(1). 72–78. 166 indexed citations

17.

Aurora, SK, et al.. (1999). The Occipital Cortex Is Hyperexcitable in Migraine: Experimental Evidence. Headache The Journal of Head and Face Pain. 39(7). 469–476. 158 indexed citations

18.

Welch, K.M.A., Yue Cao, SK Aurora, Graham C. Wiggins, & Eric M. Vikingstad. (1998). MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology. 51(5). 1465–1469. 103 indexed citations

19.

Aurora, SK, et al.. (1998). Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology. 50(4). 1111–1114. 280 indexed citations

20.

Aurora, SK. (1998). CNV in CDH. Cephalalgia. 18(8). 531–531. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact